Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: Utility of immunohistochemical markers

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 5, 2010, Pages 414-421

  Lapinski, James E ^a   Chen, Longwen ^a   Zhou, Ming ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

adrenocortical lesion; biopsy; clear cell renal cell carcinoma; immunohistochemistry; paraganglioma

Indexed keywords

CALRETININ; CARBONATE DEHYDRATASE IX; CD56 ANTIGEN; CHROMOGRANIN; CYTOKERATIN; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL MEMBRANE ANTIGEN; MELAN A; NEURON SPECIFIC ENOLASE; SYNAPTOPHYSIN; TUMOR MARKER;

ADRENAL CORTEX ADENOMA; ARTICLE; BIOPSY; CLEAR CELL RENAL CELL CARCINOMA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ADENOMA; KIDNEY CARCINOMA; MEDIASTINUM TUMOR; PARAGANGLIOMA; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; TISSUE MICROARRAY;

ADENOCARCINOMA, CLEAR CELL; ADRENAL GLAND NEOPLASMS; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MICROARRAY ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PARAGANGLIOMA; RETROPERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957579931     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181ddf7b9     Document Type: Article

References (53)

1. Eble JN, Togashi K, Pisani P. Renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 12-14.
2. Mancini V, Battaglia M, Ditonno P., et al. Current insights in renal cell cancer pathology. Urol Oncol. 2008; 26: 225-238.
3. Ng CS, Wood CG, Silverman P.M., et al. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008; 191: 1220-1232.
4. Grignon DJ, Eble JN, Bonsib S.M., et al. Clear cell renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 23-25.
5. Reuter VE, Tickoo SK Adult renal tumors. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 1863-1954.
6. Lack EE. Paragangliomas. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 669-696.
7. Kliewer KE, Cochran AJ A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal para-gangliomas. Arch Pathol Lab Med. 1989; 113: 1209-1218.
8. DeLellis RA, Mangray S. The adrenal glands. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 621-668.
9. Lack EE, Wieneke JA Adrenal glands. In: Bostwick DG, ed. Urologic Surgical Pathology. 2nd ed. Philadelphia, PA: Mosby-Elsevier; 2008: 953-1008.
10. Wenig BM. Pathology of the adrenal gland. In: Tannenbaum M, ed. Diagnostic Atlas of Genitourinary Pathology. Philadelphia, PA: Church hill-Livingstone-Elsevier; 2006: 385-398.
11. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. In: Lack EE, ed. Atlas of Tumor Pathology, 3rd Series, Fascicle 19. Washington, DC: Armed Forces Institute of Pathology; 1997: 49-152.
12. Rosai J. Adrenal gland and other paraganglia. In: Rosai J, ed. Surgical Pathology. Philadelphia, PA: Mosby; 2004: 1115-1162.
13. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immuno-histochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005; 25: 247-257.
14. Wu SL, Kothari P, Wheeler T.M., et al. Cytokeratins 7 and 20 immunoreactivity in chromophobe renal cell carcinomas and renal oncocytomas. Mod Pathol. 2002; 15: 712-717.
15. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody "renal cell carcinoma marker." Am J Surg Pathol. 2001; 25: 1485-1492.
16. Avery AK, Beckstead J, Renshaw A.A., et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000; 24: 203-210.
17. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004; 35: 697-710.
18. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol. 2002; 10: 332-338.
19. Dai L, Lu XH, Li Z.H., et al. Value of special stains and immuno-histochemistry in the diagnosis of renal epithelial neoplasms. Zhonghua Bing Li Xue Za Zhi. 2004; 33: 140-142.
20. Yang B, Ali SZ, Rosenthal DL CD10 facilitates the diagnosis of metastatic renal cell carcinoma from primary adrenal cortical neoplasm in adrenal fine-needle aspiration. Diagn Cytopathol. 2002; 27: 149-152.
21. Gokden N, Mukunyadzi P, James J.D., et al. Diagnostic utility of renal cell carcinoma marker in cytopathology. Appl Immunohisto-chem Mol Morphol. 2003; 11: 116-119.
22. Langner C, Wegscheider BJ, Ratschek M, et al. Keratin immuno-histochemistry in renal cell carcinoma subtypes and renal onco-cytomas: a systematic analysis of 233 tumors. Virchows Arch. 2004; 444: 127-134.
23. Young AN, Amin MB, Moreno C.S., et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001; 158: 1639-1651.
24. Miliaris D, Karasavvidou F, Papanikolau A., et al. KIT expression in fetal, normal adult, and neoplastic renal tissues. J Clin Pathol. 2004; 57: 463-466.
25. Langner C, Ratschek M, Rehak P., et al. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohisto-chemical analysis of 188 cases. Mod Pathol. 2004; 17: 180-188.
26. Chu P, Wu E, Weiss LM Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000; 13: 962-972.
27. Skinnider BF, Amin MB An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005; 22: 51-68.
28. Saeger W. Pathology of adrenal neoplasms. Minerva Endocrinol. 1995; 20: 1-7.
29. McNicol AM. Lesions of the adrenal cortex. Arch Pathol Lab Med. 2008; 132: 1263-1271.
30. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and Immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006; 17: 345-354.
31. Giordano TJ. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol. 2006; 17: 355-364.
32. Schroder S, Niendorf A, Achilles E., et al. Immunocytochemical differential diagnosis of adrenocortical neoplasms using the monoclonal antibody D11. Virchows Arch A Pathol Anat Histopathol. 1990; 417: 89-96.
33. Komminoth P, Roth J, Schroder S., et al. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas: implications for the differential diagnosis of adrenal gland tumors. Lab Invest. 1995; 72: 424-431.
34. Ghorab Z, Jorda M, Ganjei P., et al. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003; 11: 330-333.
35. Haak HR, Fleuren GJ Neuroendocrine differentiation of adreno-cortical tumors. Cancer. 1995; 75: 860-864.
36. Chu PG, Weiss LM Keratin expression in human tissues and neoplasms. Histopathology. 2002; 40: 403-439.
37. Kimura N, Nakazato Y, Nagura H., et al. Expression of intermediate filaments in neuroendocrine tumors. Arch Pathol Lab Med. 1990; 114: 506-510.
38. Fraga M, Garcia-Caballero T, Antunez J., et al. A comparative immunohistochemical study of phaeochromocytomas and paragan-gliomas. Histol Histopathol. 1993; 8: 429-436.
39. Miettinen M. Neuroendocrine differentiation in adrenocortical carcinoma. New immunohistochemical findings supported by electron microscopy. Lab Invest. 1992; 66: 169-174.
40. Busam KJ, Iversen K, Coplan K.A., et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998; 22: 57-63.
41. Loy TS, Phillips RW, Linder CL A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 72 neoplasms. Arch Pathol Lab Med. 2002; 126: 170-172.
42. Schroder S, Padberg BC, Achilles E, et al. Immunocytochemistry in adrenocortical tumours: a clinicomorphologic study of 72 neoplasms. Virchows Arch Pathol Anat Histopathol. 1992; 420: 65-70.
43. Lloyd RV, ed. Endocrine Pathology: Differential Diagnosis and Molecular Advances. Totowa, New Jersey: Humana Press; 2004.
44. Erickson LA, Lloyd RV Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol. 2004; 11: 175-189.
45. McNicol AM. Histopathology and Immunohistochemistry of adrenal medullary tumors and paragangliomas. Endocr Pathol. 2006; 17: 329-336.
46. Ellison DA, Parham DM Tumors of the autonomic nervous system. Am J Clin Pathol. 2001; 115(SUPPL. 1): S46-S55.
47. Wasserman PG, Savargaonkar P. Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngol Clin North Am. 2001; 34: 845-862, v-vi.
48. Wick MR. Immunohistology of neuroendocrine and neuroectoder-mal tumors. Semin Diagn Pathol. 2000; 17: 194-203.
49. Arola J, Liu J, Heikkila P., et al. Expression of inhibin a in adrenocortical tumours reflects the hormonal status of the neoplasm. J Endocrinol. 2000; 165: 223-229.
50. Munro LMA, Kennedy A, McNicol AM The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J Endocrinol. 1999; 161: 341-347.
51. Zhang PJ, Genega EM, Tomaszewski J.E., et al. The role of calretinin, inhibin, melan-A, bcl-2, and c-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003; 16: 591-597.
52. Cho EY, Ahn GH Immunoexpression of inhibin a-subunit in adrenal neoplasms. Appl Immunohistochem Mol Morphol. 2001; 9: 222-228.
53. Hoang MP, Amirkhan RH Inhibin alpha distinguishes hemangio-blastoma from clear cell renal cell carcinoma. Am J Surg Pathol. 2003; 27: 1152-1156.